These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9917132)

  • 1. Association of p53 accumulation with TP53 mutations, loss of heterozygosity at 17p13, and DNA ploidy status in 273 colorectal carcinomas.
    Clausen OP; Lothe RA; Børresen-Dale AL; De Angelis P; Chen Y; Rognum TO; Meling GI
    Diagn Mol Pathol; 1998 Aug; 7(4):215-23. PubMed ID: 9917132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors.
    Lothe RA; Fossli T; Danielsen HE; Stenwig AE; Nesland JM; Gallie B; Børresen AL
    J Natl Cancer Inst; 1992 Jul; 84(14):1100-8. PubMed ID: 1619684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of p53 expression, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (stages IB and II).
    Baretton GB; Vogt M; Müller C; Diebold J; Schneiderbanger K; Schmidt M; Löhrs U
    Scand J Gastroenterol; 1996 May; 31(5):481-9. PubMed ID: 8734346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
    Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
    Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of genetic alterations associated with DNA diploidy, aneuploidy and multiploidy in gastric cancers.
    Sugai T; Habano W; Jiao YF; Suzuki M; Takagane A; Nakamura S
    Oncology; 2005; 68(4-6):548-57. PubMed ID: 16037688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas.
    Campo E; Miquel R; Jares P; Bosch F; Juan M; Leone A; Vives J; Cardesa A; Yague J
    Cancer; 1994 Jun; 73(12):2913-21. PubMed ID: 8199988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas.
    Bosari S; Viale G; Bossi P; Maggioni M; Coggi G; Murray JJ; Lee AK
    J Natl Cancer Inst; 1994 May; 86(9):681-7. PubMed ID: 8158699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of genetic alterations, classified according to their DNA ploidy pattern, in the progression of colorectal adenomas and early colorectal carcinomas.
    Sugai T; Takahashi H; Habano W; Nakamura S; Sato K; Orii S; Suzuki K
    J Pathol; 2003 Jun; 200(2):168-76. PubMed ID: 12754737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival.
    Lanza G; Maestri I; Dubini A; Gafa R; Santini A; Ferretti S; Cavazzini L
    Am J Clin Pathol; 1996 May; 105(5):604-12. PubMed ID: 8623770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordance of p53 mutations of synchronous colorectal carcinomas.
    Eguchi K; Yao T; Konomoto T; Hayashi K; Fujishima M; Tsuneyoshi M
    Mod Pathol; 2000 Feb; 13(2):131-9. PubMed ID: 10697269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic alterations in DNA diploid, aneuploid and multiploid colorectal carcinomas identified by the crypt isolation technique.
    Sugai T; Habano W; Nakamura S; Sato H; Uesugi N; Takahashi H; Jiao Y; Yoshida T; Itoh C
    Int J Cancer; 2000 Nov; 88(4):614-9. PubMed ID: 11058879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.
    Erill N; Colomer A; Verdú M; Román R; Condom E; Hannaoui N; Banús JM; Cordon-Cardo C; Puig X
    Diagn Mol Pathol; 2004 Dec; 13(4):217-23. PubMed ID: 15538112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma.
    Slebos RJ; Baas IO; Clement M; Polak M; Mulder JW; van den Berg FM; Hamilton SR; Offerhaus GJ
    Br J Cancer; 1996 Jul; 74(2):165-71. PubMed ID: 8688317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TP53 tumour suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinicopathological variables.
    Meling GI; Lothe RA; Børresen AL; Graue C; Hauge S; Clausen OP; Rognum TO
    Br J Cancer; 1993 Jan; 67(1):93-8. PubMed ID: 8427784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 mutations and DNA ploidy in colorectal adenocarcinomas.
    Campomenosi P; Assereto P; Bogliolo M; Fronza G; Abbondandolo A; Capasso A; Bellomo PF; Monaco R; Rapallo A; Sciutto A; Orecchia R; Geido E; Giaretti W
    Anal Cell Pathol; 1998; 17(1):1-12. PubMed ID: 9807634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 expression and DNA ploidy pattern in Egyptian colorectal carcinoma.
    Zalata KR; Leech SH; Ming SC; Nasif WA; Nada NA; Mohamed IE; Atallah AM; Gad-el-Hak NA
    Hepatogastroenterology; 2002; 49(47):1225-9. PubMed ID: 12239910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allelic losses of 17p, 5q, and 18q loci in diploid and aneuploid populations of multiploid colorectal carcinomas.
    Sugai T; Habano W; Nakamura S; Sato H; Uesugi N; Orii S; Itoh C; Katoh R
    Hum Pathol; 2000 Aug; 31(8):925-30. PubMed ID: 10987252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma.
    McManus DT; Murphy M; Arthur K; Hamilton PW; Russell SE; Toner PG
    J Pathol; 1996 Jun; 179(2):177-82. PubMed ID: 8758210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas.
    Colomer A; Erill N; Verdú M; Roman R; Vidal A; Cordon-Cardo C; Puig X
    Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):130-7. PubMed ID: 12777996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.